Immunovant Q1 net loss $40.4M; initiates pivotal MG trial, TED trials on track

Immunovant, Inc.

2023-Q1 EPS reported -$0.35

Net loss of $40.4M ($0.35/share) vs $30.5M ($0.31) YoY; R&D expenses up to $28.4M from $18.7M.
Cash $427M as of June 30; expects runway into calendar 2025 despite $31M in CMC/clinical payments in Q1.
Pivotal batoclimab trial in Myasthenia Gravis initiated June 2022; top-line data expected H2 2024.
FDA alignment on two pivotal trials in Thyroid Eye Disease; trials to start H2 2022, data H1 2025.
Investor call Sep 7 to announce two new batoclimab indications and third pivotal trial for 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.